Work

Phase I Trial of Intravenous IL-4 Pseudomonas Exotoxin Protein (NBI-3001) in Patients with Advanced Solid Tumors That Express the IL-4 Receptor

Year: 2005

Type: article

Study design: Clinical Trial

Source: Journal of Immunotherapy

DOI: 10.1097/01.cji.0000162782.86008.ml

Authors: Linda Garland, Barbara Gitlitz, Scot Ebbinghaus, Henry Pan, Hans de Haan, Raj K Puri, Daniel Von Hoff, Robert Figlin

Institutions: University of Arizona, University of Southern California, USC Norris Comprehensive Cancer Center, University of Arizona Cancer Center, Neurocrine Biosciences (United States), National Institutes of Health, Center for Biologics Evaluation and Research, United States Food and Drug Administration, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center

Language: English

Topic: Toxin Mechanisms and Immunotoxins

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2064486972

FWCI: 1.405

Cites: 33

Cited by: 50

Related to: 10